Australia's Island Pharmaceuticals jumps on buying antiviral program

Island Pharmaceuticals

09/07/2025 01:50

** Island Pharmaceuticals ILA.AX jumps as much as 13.8% to A$0.165, highest since June 17

** Drug company signs asset purchase agreement to acquire Galidesivir antiviral program from BioCryst Pharmaceuticals Inc BCRX.O

** Galidesivir is a clinical-stage antiviral molecule with broad spectrum of activity in more than 20 RNA viruses, including high-priority threats such as Ebola and Marburg

** YTD, ILA down 11.8%

 (Reporting by Sherin Sunny in Bengaluru)

 ((Sherin.Sunny@thomsonreuters.com;))